Pictured left, Dr Gabriel Leen, founder of UL spinout company is a partner in one of sixteen projects who have been awarded a total of €65m from the Irish Government’s Disruptive Technologies Innovation Fund.
The successful project: FerrTest, which is led by Radisens Diagnostics, will develop a Point-of-care iron stores/ferritin diagnostic, which is particularly relevant to at-risk blood donors, women and children. PolyPico Technologies (www.polypico.com), the Irish Manufacturing Research (Iwww.imr.ie), and Trinity College Dublin (www.tcd.ie) are partnering with Radisens Diagnostics (www.radisens.com) to make this possible.
Ferritin is the principal storage protein for iron in tissues and is involved in its uptake, accumulation and release in cells. Current clinical measurement of ferritin is restricted to laboratory testing as no suitable quantitative point-of-care in vitro diagnostic solution exists. The FerrTest project aims to both develop disruptive technologies and automated manufacturing processes for a quantitative point-of-care platform to measure ferritin.